Pair page
Dihexa with DS5
Mechanism-tag overlap and published literature for Dihexa and DS5, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
angiotensin-iv-analog-hgf-positive-modulatorpeptidomimetic
blenddihexa-semax-nootropic-stack
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Dihexa and DS5 have published these mechanism-level observations. Not a co-administration recommendation.
The HGF/c-Met leg of DS5. Full profile covers the mechanism, the retracted Benoist 2014 paper, the McCoy 2013 expression of concern, and the LIFT-AD failure. Users concerned about dihexa's evidence record often drop this component.
Quick facts
Dihexa
DS5
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2024 | Dihexa | Athira Pharma, Inc. Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease. Press release, late 2024. (NCT04488419 — primary endpoint not met.) | human trial, Phase 2 |
| 2023 | Dihexa | Athira Pharma, Inc. Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton in Parkinson's Disease Dementia and Dementia with Lewy Bodies. Press release, December 2023. (NCT04831281.) | human trial, Phase 2 |
| 2022 | Dihexa | Athira Pharma, Inc. Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease. Press release, 2022. (NCT04491006.) | human trial, Phase 2 |
| — | Dihexa | Hua X, Church K, Walker W, L'Hostis P, Viardot G, Danjou P, Hendrix S, Moebius HJ. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease. (Fosgonimeton Phase 1… | human trial, Phase 1 |
| 2015 | Dihexa | Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: A new target for the treatment of Alzheimer's disease. J Alzheimers Dis. 2015;45(4):985-1000. PMID: 25649658. (Mechanistic review.) PMID 25649658 | human study |
| 2021 | Dihexa | Sun X, Deng Y, Liang J, Lin Y, Song J, Zhao S, Zhuang G, Jia Z. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021 Oct 28;11(11):1421. PMID: 34827487. (Independent Chinese group; APP/PS1 m… PMID 34827487 | preclinical, in vivo |
| 2025 | Dihexa | FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025–2026. | regulatory / registry |
| 2022 | Dihexa | Stem Cell Research & Therapy. Dihexa as adjunct in peripheral nerve repair. 2022 Apr 11;13(1):159. PMID: 35410439. PMCID: PMC8996222. PMID 35410439 | research article |
| 2015 | Dihexa | Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015 Feb;125:26-46. PMID: 25455861. (Comprehensive Wright/Harding review.) PMID 25455861 | research article |
| 2015 | Dihexa | Uribe PM, Kawas LH, Harding JW, Coffin AB. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Front Cell Neurosci. 2015 Jan 28;9:3. PMID: 25674052. PMCID: PMC4309183. (Independent dihexa hair-cell preservation study.) PMID 25674052 | research article |
| 2015 | Dihexa | Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015 May 12;4(5):939-52. PMID: 25937370. PMID 25937370 | research article |
| 2014 | Dihexa | Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014… PMID 25187433 | research article |
| 2024 | DS5 | Athira Pharma, Inc. Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease. Press release, late 2024. (NCT04488419 — primary endpoint not met.) | human trial, Phase 2 |
| 2018 | DS5 | Gusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68. | human study |
| 2006 | DS5 | Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of adrenocorticotropin (4-10), activates expression of BDNF in rat basal… | preclinical, in vivo |
| 2026 | DS5 | WADA Prohibited List 2026. World Anti-Doping Agency. | regulatory / registry |
| 2025 | DS5 | FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025–2026. | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have Dihexa and DS5 been studied together?
Researchers have published mechanistic-level co-administration discussion of Dihexa and DS5. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Dihexa and DS5 share?
Dihexa and DS5 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Dihexa and DS5?
Dihexa: Investigational / Research only. DS5: Research only. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Dihexa and DS5?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Dihexa profile and the DS5 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026